Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT00614523 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

MDS
Myelodysplastic Syndromes
Thrombocytopenia

Interventions

DRUG: Placebo
BIOLOGICAL: Romiplostim

Sponsor

Amgen